Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the JPMorgan Healthcare conference.
Here are the key catalysts that could prove market moving in the unfolding week.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Conferences
American Society of Clinical Oncology, or ASCO, Gastrointestinal Cancers Symposium: Jan. 23-25 in San Francisco, California
PDUFA Dates
The FDA is scheduled to rule on Epizyme Inc's (NASDAQ:EPZM) tazemetostat, an experimental drug to treat metastatic or locally advanced, unresectable epithelioid sarcoma. FDA's Oncologic Drugs Advisory Committee, which met Dec. 18 to discuss the NDA for tazemetostat, unanimously recommended approval of the drug. The PDUFA date is set for Thursday.
The regulatory agency will announce Thursday its verdict on Merck & Co., Inc.'s (NYSE:MRK) NDA and sNDA for DIFICID (fidaxomicin) to treat Clostridium difficile infections. The NDA pertains to an oral suspension formulation and the sNDA is for the label expansion of the indication to treat children, ages six and older. Dificid, in tablet formulation, has already been approved to treat Clostridium difficile infections in adults 18 years and older.
See Also: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Clinical Readouts
ASCO Gastrointestinal Cancers Symposium Presentations
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM): Phase 1 Cohort 5B new translational data for its pancreatic cancer experimental drug BPX-601 (Friday)
Forty Seven Inc (NASDAQ:FTSV): Phase 1b data for magrolimab in combination with cetuximab in colorectal cancer
Earnings
Wednesday
Abbott Laboratories (NYSE:ABT) (before the market open)
Johnson & Johnson (NYSE:JNJ) (before the market open)
Thursday
Intuitive Surgical, Inc. (NASDAQ:ISRG) (after the market close)
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.